恩扎鲁胺
医学
前列腺癌
肿瘤科
内科学
随机对照试验
联合疗法
放射性配体
雄激素受体
癌症
受体
作者
Finn Edler von Eyben,Irene Virgolini,Richard P. Baum
出处
期刊:Cancers
[MDPI AG]
日期:2024-07-12
卷期号:16 (14): 2520-2520
标识
DOI:10.3390/cancers16142520
摘要
In 2021, two randomized controlled trials (RCTs), TheraP and VISION, demonstrated that 177Lu-PSMA-617 as monotherapy was more effective for the decline of PSA than the comparator third-line treatments. Methods: Our review summarizes new RCTs that add to the use of radioligand therapy (RLT) for patients with high-risk prostate cancer (PCa). Results: Four past and present RCTs included 1081 patients. An RCT, ENZA-p, studied first-line treatment of patients with metastatic castration-resistant PCa (mCRPC). A combination of enzalutamide (ENZA) and 177Lu-PSMA-617 gave longer progression-free survival than ENZA as monotherapy. Other RCTs of patients with mCRPC, including the PSMAfore, and SPLASH trials, showed 177Lu-PSMA-617 as second-line treatment gave better progression-free survival than androgen receptor pathway inhibitors (combined p value < 6.9 × 10−6). Conclusions: Patients with PCa gain if they are given PSMA-RLT early in the treatment of PCa and as part of combination therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI